Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma (Q41719867)

8 October 2017

title

Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma (English)

1 reference

8 October 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26004934%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Semra Paydas

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26004934%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Emine Bağır

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26004934%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Vehbi Ercolak

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26004934%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Melek Ergin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26004934%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

26 May 2015

1 reference

8 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26004934%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26004934%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26004934%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

1545-1552

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26004934%20AND%20SRC:MED&resulttype=core&format=json

Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Clinical impact of checkpoint inhibitors as novel cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2

RNA fingerprints provide direct evidence for the inhibitory role of TGF and PD-1 on CD4+ T cells in Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00277-015-2403-2